story of the week
Rituximab vs Intravenous Cyclophosphamide in Patients With Connective Tissue Disease–Associated Interstitial Lung Disease in the UK
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial
Lancet Respir Med 2022 Nov 11;[EPub Ahead of Print], TM Maher, VA Tudor, P Saunders, MA Gibbons, SV Fletcher, CP Denton, RK Hoyles, H Parfrey, EA Renzoni, M Kokosi, AU Wells, D Ashby, M Szigeti, PL MolyneauxFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.